41%, 45% and 50%, respectively). The diagnosis of avascular osteonecrosis of the femoral head (unilateral n=2 and bilateral n=1) was documented by CT scan. Only one patient underwent surgical arthroplasty. In resource-limited settings, avascular osteonecrosis is uneasy to diagnose and unlikely to be appropriately treated. Physicians should be aware of its symptoms and risk factors, including HIV infection and antiretroviral therapy. Future studies should explore whether these risk factors might include haemoglobin AS sickle cell disease, a common trait in the West African general population.
In industrialized countries, avascular osteonecrosis (AVON) is more frequent in HIV-infected patients than in the general population [1] [2] [3] [4] . In HIV-infected patients, this disease has been associated with antiretroviral therapy (ART)-induced hyperlipidaemia and lipodystrophy, as well as with inflammatory mechanisms related to HIV infection itself [1] [2] [3] [4] .
In sub-Saharan Africa, few studies on long-term side effects of antiretroviral drugs have been published so far [5] . None of them reported AVON.
Here, we report three cases of AVON of the femoral head in HIV-infected adults admitted to the Department of Infectious Diseases of the Treichville Hospital, Abidjan, Côte d'Ivoire.
Reports

Patient 1
A 33-year-old HIV type-1 (HIV-1)-infected patient was admitted in February 2005 with a pain lasting 4 months of the right hip and progressive impaired mobility.
He had been receiving ART since October 1998. His pre-ART characteristics were clinical CDC stage BIII, CD4 + T-cell count 86 cells/mm 3 and plasma HIV-1 viral load (VL) 5.07 log 10 copies/ml. In October 1998 he started a two-drug therapy with zidovudine and didanosine. In December 1998 (CD4 + T-cell count 202 cells/mm 3 and VL 2.59 log 10 copies/ml), 3 and VL 4.27 log 10 copies/ml). The latter regimen had been taken for 23 months when the first symptoms of AVON occurred.
Case report
At hospital admission, his weight was 68 kg and his body mass index (BMI) was 24.11 kg/m 2 . He declared that he had been drinking a mean of three glasses of beer per day for the past 10 years, and a smoking consumption estimated at eight boxes per year. He had no history of traumatism, exposure to ionizing radiation or corticosteroid treatment. The CT scan showed a Ficat stage II-III AVON of the right femoral head and a normal left femoral head. The haemoglobin electrophoresis showed 41% of haemoglobin S. The other risk factor was hypertriglicerydaemia ( Table 1) .
The patient underwent surgical arthroplasty of the right hip in August 2005. Tenofovir was replaced with abacavir, but lopinavir/ritonavir had to be maintained as it was the only viable option for this patient at that time in Côte d'Ivoire.
Patient 2
A 44-year-old HIV type-2 (HIV-2)-infected patient was admitted in February 2005 with a bilateral hip pain lasting 2 months and impaired mobility.
He The patient received a non-surgical treatment. Abacavir and lamivudine were maintained, and lopinavir/ritonavir was replaced with indinavir/ritonavir because of the hypertriglyceridaemia. Despite a heavy disability, he was not able to access surgery because of a lack of financial resources.
Patient 3
A At hospital admission, his weight was 66 kg and his BMI was 20.37 kg/m 2 . He had moderate mixedpatterns lipodystrophy (lipoatrophy with wasting of extremities and lipohypertrophy with fat accumulation in the abdomen). He declared that he had been drinking a mean of two glasses of beer per day for the past 10 years. He had a history of traffic road accident, with no traumatism of the hips. He had no history of tobacco consumption, exposure to ionizing radiation or corticosteroid treatment. The CT scan showed a Ficat stage II-III AVON of the right femoral head and a normal left femoral head. The haemoglobin electrophoresis showed 50% of haemoglobin S. The other risk factors were lipodystrophy and hypertriglicerydaemia (Table 1) . Abacavir and lamivudine were maintained, and lopinavir/ritonavir was replaced with indinavir/ ritonavir because of lipid profile. Despite the stage of AVON, surgery was not performed because of the limited financial resources of the patient.
Discussion
This is a small and descriptive case report study, with the primary aim to draw the attention of clinicians from resource-limited settings to AVON as a potential complication in HIV-infected patients, and not to prove the association between AVON and ART or sickle cell disease. To our knowledge, these are the first reports of AVON in HIV-infected patients receiving ART in subSaharan Africa.
In industrialized countries, AVON has been estimated to be 5-10× more frequent in HIV-infected patients receiving ART than in non-HIV-infected patients [1] [2] [3] [4] . In HIV-infected and HIV-negative patients, osteonecrosis has also been associated with steroids and alcohol use [7] . In patients receiving ART, a long time since HIV seroconversion, a low CD4 + T-cell count nadir, a long time on ART, a protease inhibitor drug-related hyperlipidaemia, as well as lipodystrophy have been identified as risk factors for AVON [1] [2] [3] [4] . Our three patients had been receiving ART for >3 years, and had several other risk factors. The three of them also had heterozygote sickle cell disease.
Before the ART era in West Africa, AVON was mostly diagnosed in individuals with haemoglobin SS and haemoglobin SC sickle cell disease [8] . It has been suggested, however, that heterozygote AS sickle cell disease might also slightly increase the risk for AVON in patients with a high percentage of haemoglobin S [9] . In West Africa, 10-25% of the population is estimated to have the haemoglobin AS trait [8] . If this trait is a minor risk factor for AVON in the HIV-negative population, it would probably play a growing role in the HIV era combined with the other risk factors found in our three patients. This role would also become more visible as the number of patients receiving these drugs is likely to increase over time because of the quick scaling-up of patients accessing ART, including those under second-line therapy with protease-inhibitor-based regimens [10, 11] . By contrast, one should be very cautious in interpreting the current evidence, which is still limited. The respective role of sickle cell diseases (if any), HIV infection, immunosuppresion, inflammation, alcohol, dyslipidaemia and lipodystrophy as risk factors for AVON still deserve further evaluation, as do the role of antiretroviral drugs themselves. Because the latter (including protease inhibitors) decrease inflammation and increase CD4 + T-cell count, they could also decrease the rate of AVON in the general population of HIV-infected patients, and at the same time act as cofactors associated with AVON in some groups of patients with multiple risk factors, as has been suggested for cardiovascular diseases [12] .
In sub-Saharan Africa, AVON is difficult to diagnose and unlikely to be properly treated. A French study showed that specificity of standard X-ray, CT scan and scintigraphy is 80%, 96.1% and 100%, respectively, and sensitivity is 68.2%, 73% and 78.8% [13] . However, the best method to diagnose AVON at any stage is magnetic resonance imaging, with a specificity of 98% and a sensitivity of 97% [14] . Unfortunately, this method is too expensive for the majority of HIV-infected patients in Côte d'Ivoire.
Physicians should be aware of the symptoms of AVON and of its potential risk factors, including HIV infection, ART, steroids, alcohol and dyslipidaemia. Further studies should explore whether these risk factors might include haemoglobin AS sickle cell disease, a common trait in the West African general population.
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